NCT06841692 Diuretic Testing in Chronic Kidney Disease
| NCT ID | NCT06841692 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erasmus Medical Center |
| Condition | Kidney Disease, Chronic |
| Study Type | INTERVENTIONAL |
| Enrollment | 86 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2029-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 86 participants in total. It began in 2025-04-01 with a primary completion date of 2029-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to predict the progression of chronic kidney disease by diuretic testing in patients with chronic kidney disease. The main questions it aims to answer are: Does a worse result of a diuretic test predict the progression of chronic kidney disease? If there is a comparison group: Researchers will compare the diuretic test in patients with chronic kidney disease to healthy participants to see if the results are different in a healthy kidney. Participants will undergo diuretic testing. This involves the administration of bumetanide and hydrochlorothiazide with subsequent blood and urine collections.
Eligibility Criteria
Inclusion Criteria for CKD subjects: * CKD stage G3 (creatinine-based eGFR 30-59 mL/min/1.73m2) during the last outpatient visit Inclusion Criteria for Healthy subjects: • eGFR within the expected range for age (a decline of 1 ml/min/1.73 m2 per year starting from age 40 is considered the normal age-related decline in kidney function Exclusion Criteria: * Known intolerance or allergy to the diuretics * Current systemic chemotherapy for malignancy * Kidney transplant recipient * Use of calcineurin-inhibitors * Life expectancy \< 12 months * Current immunosuppressive treatment for glomerulonephritis * Incapacitated subjects or subjects who are deemed unfit to adequately adhere to instructions from the research team * Hypokalemia or hyperkalemia (K+ \< 3.0mmol/L or K+ \> 5.5 mmol/L) at inclusion visit * Hypo- or hypernatremia (Na+ \< 130 mmol/L or Na+ \> 150mmol/L) at inclusion visit * Inherited tubulopathy as the cause of CKD * Autosomal dominant polycystic or tubulointerstitial kidney disease causing CKD * Clinically relevant heart failure (New York Heart Association class III or IV) * Therapy-resistant hypertension, defined as systolic blood pressure \> 180mmHg at the inclusion visit * Current treatment with inhibitors of Organic anion transporters: probenecid, pravastatin, cimetidine, cephalosporins, acetazolamide \[22\] * Active hepatitis during last outpatient visit * Liver cirrhosis in advanced stage (Child-Pugh B or C) * Active drug- or alcohol abuse * Not being able to tolerate a 28-day washout of one of the drugs interfering with diuretic testing. * Women who are pregnant, breastfeeding, or planning on becoming pregnant before the test day
Contact & Investigator
Ewout J. Hoorn, MD, PhD
PRINCIPAL INVESTIGATOR
Erasmus Medical Center
Frequently Asked Questions
Who can join the NCT06841692 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Disease, Chronic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06841692 currently recruiting?
Yes, NCT06841692 is actively recruiting participants. Contact the research team at s.beckmann@erasmusmc.nl for enrollment information.
Where is the NCT06841692 trial being conducted?
This trial is being conducted at Rotterdam, Netherlands.
Who is sponsoring the NCT06841692 clinical trial?
NCT06841692 is sponsored by Erasmus Medical Center. The principal investigator is Ewout J. Hoorn, MD, PhD at Erasmus Medical Center. The trial plans to enroll 86 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.